Lakewood-Amedex Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing
LABT sits 26% above its 52-week low of $0.59.
Summary
Lakewood-Amedex Biotherapeutics Inc. announced a 1-for-10 reverse stock split, effective June 19, 2026, to help maintain its Nasdaq listing.
Key Events · Corporate Governance and Compliance · LABT
-
1-for-10 Reverse Stock Split Approved
The company filed a Certificate of Change to effectuate a 1-for-10 reverse stock split of its common stock, approved by the Board of Directors on June 1, 2026.
-
Effective Dates
The reverse stock split becomes effective at 4:01 p.m. ET on June 19, 2026, with split-adjusted trading beginning on Nasdaq on June 22, 2026.
-
Share Count Reduction
The split will reduce outstanding common shares from approximately 17,506,577 to 1,750,789 and authorized shares from 125,000,000 to 12,500,000.
-
Nasdaq Listing Maintained
The common stock will continue to trade on The Nasdaq Capital Market under the existing symbol 'LABT', with a new CUSIP number (51255A201).
Analysis · LABT · Life Sciences
This reverse stock split is a critical defensive maneuver for Lakewood-Amedex, a company previously flagged with a 'going concern' warning. The 1-for-10 split will increase the per-share price, likely to meet Nasdaq's minimum bid price requirement and avoid delisting. While necessary for continued public trading, reverse splits often reflect underlying financial distress and can be viewed negatively by investors, as they do not change the company's fundamental value but reduce the number of shares outstanding.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.59 to $9.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.